Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis

• Published in: Journal of medicinal chemistry 2024-07, Vol.67 (14), p.12085-12098
• Main Authors: Shi, Zihan, Liu, Xianyan, Wu, Shuohan, Song, Nazi, Tang, Qinglin, Li, Haonan, Luo, Suijia, Chan, Albert S. C., Cai, Xiaoqing, Liu, Han, Jiang, Xianxing
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis - drug effects; Drug Discovery; Endoplasmic Reticulum Stress - drug effects; Hepatic Stellate Cells - drug effects; Hepatic Stellate Cells - metabolism; Hepatic Stellate Cells - pathology; Humans; Liver Cirrhosis - drug therapy; Liver Cirrhosis - metabolism; Liver Cirrhosis - pathology; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Peptides, Cyclic - chemical synthesis; Peptides, Cyclic - chemistry; Peptides, Cyclic - pharmacology; Peptides, Cyclic - therapeutic use; Reactive Oxygen Species - metabolism; Receptors, Cannabinoid - metabolism; Receptors, G-Protein-Coupled - antagonists & inhibitors; Receptors, G-Protein-Coupled - metabolism; Structure-Activity Relationship
• ISSN: 0022-2623; 1520-4804; 1520-4804
• DOI: 10.1021/acs.jmedchem.4c00834

Liver fibrosis is a condition characterized by aberrant proliferation of connective tissue in the liver resulting from diverse etiological factors. G protein-coupled receptor GPR55 has recently been identified as a regulator of liver diseases. Herein, we report the discovery of a cyclic peptide P1-1 that antagonizes GPR55 and suppresses collagen secretion in hepatic stellate cells. The alanine scanning and docking study was carried out to predict the binding mode and allowed for further structural optimization of peptide antagonists for GPR55. The subsequent in vivo study demonstrated that P1-1 ameliorates CCl4-induce and MCD-diet-induce acute liver inflammation and fibrosis. Further study indicates that P1-1 reduces reactive oxygen species (ROS) production, attenuates ER stress, and inhibits mitochondria-associated hepatocyte apoptosis. In this work, we provided the first successful example of antagonizing GPR55 for liver inflammation and fibrosis, which validates GPR55 as a promising target for the treatment of liver fibrosis and affords a high-potent GPR55 antagonist P1-1 as a potential therapeutic candidate.